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Summary.-In view of the concern over the rising incidence of malignant melanoma
in many parts of the world, and the suggestion that emigrants of Scottish and Irish
descent have a higher incidence of melanoma in North America and Australia, a
Scottish Melanoma Group has been formed to study epidemiological, pathological
and therapeutic aspects of the tumour. In 1979, 260 histologically proven primary
cutaneous malignant melanomas of the skin presented. This represents an incidence
of5 1/105 for Scotland as a whole. Studies over the next5 years will determine whether
the incidence of melanoma is rising in Scotland as rapidly as in other parts of the
world.
RECENT EPIDIEMIOLOGICAL STULDIES on
cutaneous malignant melanoma in various
parts of the world have documented a
rapid rise in the incidence of this malig-
nancy in white-skinned races (Lee &
Carter, 1970; Elwood et al., 1974; Water-
house et al., 1976; Magnus, 1981; Teppo
et al., 1978; Holman et al., 1980). Three
areas in which detailed sequential epi-
demiological studies have been performed
are Queensland (Australia), Connecticut,
and Arizona (U.S.). The figures from
Queensland show a sharp increase in
incidence from 16/105 in 1963-69 to
32-7/105 in 1977 (Little et al., 1980),
which is the highest recorded incidence
of melanoma anywhere in the world. The
Connecticut incidence rate of 1 1/105
in 1935 rose to 5-8/105 by 1974, with a
more rapid increase apparent in males
(Houghton et al., 1980). The recent study
from Arizona demonstrates a dramatic
quadrupling of the incidence of melanoma
over a 10-year period, from 6 5/105 in
1969 to 27.2/105 in 1978 (Schreiber et al.,
1981). This alarming rate of increase is
the most rapid yet recorded, and applies
exclusively to those ofNorthern European
descent.
Studies from both Queensland and
North America suggest that there is a,
higher incidence of melanoma in that
proportion of the population who are of
"Celtic" descent. Large numbers of Scots
and Irish emigrated to Queensland in the
19th century, and events such as the
failure of the Irish potato harvest in
1845-46 and the highland clearances of
the first halfofthe 19th century prompted
a similar emigration to North America.
Attempts have been made to determine
the proportion of melanoma patients
descended from Scots or Irish emigrants
in these areas by compiling a list of
surnames considered to be of Celtic
origin. In both Queensland and Boston
the incidence of melanoma in the popula-
tion bearing suich names is significantly
higher (Lane Brown et al., 1971; Lane
Brown & Melia, 1973).
There is therefore good circumstantial
evidence to suggest that individuals from
Scotland and Ireland who emigrated to
the sunnier climates of Queensland or
certain parts of North America, and their
descendants, have a higher incidence of
cutaneous malignant, melanoma than other
European emigrants. Surprisingly there
is sparse information on the epidemiology
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or Irish populations in their native
environment. The only recent survey
carried out retrospectively in South-east
Scotland studied a population of about
one quarter that of Scotland, and deter-
mined a mean annual incidence during the
period 1971-1976 of 4.6/105, with females
affected almost twice as often as males
(Pondes et al., 1981). More information,
based on prospective studies, is obviously
needed to establish (1) the true incidence
of malignant melanoma arising in either
Scots or Irish in their native environment
and (2) whether the rapid increase in
incidence observed recently among descen-
dants of Scottish emigrants is also being
experienced by the native Scottish popu-
lation in situ.
THE SCOTTISH MELANOMA GROUP
For these reasons, and because of the
presence in Scotland of individuals with a
specific interest in the biology of cutaneous
malignant melanoma, the Scottish Melanoma
Group (SMG) was formed in June 1978.
The specific aims of the group at this time
were firstly to ensure rapid and accurate
registration of all patients with cutaneous
malignant melanoma presenting in Scotland,
secondly to encourage pathologists in the
area to use modern terminology and
techniques of proven prognostic significance
in reporting malignant melanomas, thirdly to
follow all patients from registration to death
to determine changes in mortality, and
lastly to define accurately the type of surgery
being carried out on patients with primary
cutaneous melanoma.
The reason for selecting these 4 objectives
for initial study by the group was that
precise details on all these aspects were not
currently available for malignant melanoma
in Scotland, though they had been established
in other parts of the world as significant
variables to be considered in the design
of any collaborative trial on the treatment
of melanoma. Knowledge of the incidence
of the tumour and basic clinical information
is essential in the statistical design of any
trial involving such a rare tumour. Strati-
fication according to pathological variables
of prognostic significance has also been
shown to be essential for the validity of any
therapeutic trial on melanoma.
Scotland is considered to be a particularly
useful site for epidemiological study for
various other reasons. The population is
relatively static, and tracer studies therefore
present few problems. There is still a degree
of genetic homogeneity which is no longer
found in many parts of the world, especially
in the United States, and as Scotland is a
small country information can be readily
obtained from all parts, since patients from
the more remote areas, including the islands,
are referred to the central belt and are easily
registered and followed up.
The SMG works in close collaboration with
the 5 Scottish cancer registries and the
presence of a representative of the Informa-
tion Services Division of the Scottish Health
Service on the central committee ofthe group
facilitates this liaison. Initially the SMG
and the cancer registries will compare
registration figures as a cross-check on the
completeness of registration in both groups.
However, it is hoped that in the long term
all cases will be registered only by the cancer
registries, leaving the SMG free to concentrate
on clinical, pathological and therapeutic
studies.
Five multidisciplinary local melanoma
groups based in Glasgow, Edinburgh, Dundee,
AberdeenandInvernesshavebeenestablished.
Disciplines represented in the groups include
dermatologists, pathologists, oncologists, sur-
geons, plastic surgeons, radiotherapists, epi-
demiologists and statisticians. Local meetings
are convened by regional representatives
who report on area activities to the Central
Committee. Patients are registered locally
by the regional coordinator of these groups
and as a result local interest and involve-
ment have been maintained.
RESULTS OBTAINED BY SMG
Registration began on 1 June, 1978.
The figures for the first 6 months
were used as a basis to initiate and
improveregistration.Those casesregistered
between 1 January and 31 December
1979, are recorded in Table I. Two
points are immediately apparent. The
SMG national figure (5-1/105 p.a.) is
considerably higher than the unpublished
figure of 301105 from the Scottish Cancer
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TABLE I.-Primary cutaneous melanomas presenting in Scotland in 1979
Total
no.
West of Scotland
Lothian
Grampian
Tayside
Inverness
Totals
Incidence/105
141 4-9
67 5-6
18 3-5
23 5-7
11 5-3
260 5-1
TABLE II.- Distribution ofprimary cutaneous melanomas by age and sex
Scotland, 1979
Total
male Age
0-9 0
10-19 0
20-29 6
30-39 10
40-49 12
50-59 17
60-69 22
70+ 14
81
(1 missing value)
Age-adjusted incidence for
population
Male Total Female Total
incidence/105 female incidence/105 F/M
0
0
1-5
3-0
4-2
5.9
10-0
6-2
3-5
3-7
0
1
12
12
26
36
42
43
172
(6 missing values)
0
2-6
3-1
3-7
8-6
11 -3
15-2
12-3
6-6
2-0
1 -2
2-2
2-1
1.9
3 0
2-12
Incidence
F/M
2-2
1-2
2-0
1.9
1-5
2-0
6-2
TABLE III.-Distribution of primary cutaneous malignant melanoma,
by site
Scotland, 1979,
Face
Head and neck
Trunk
Lower limb: (21)
Leg and dorsum foot
Sole
Subungual
Upper limb: (8)
Arm and dorsum hand
Palm
Subungual
Mucosal
Not stated
Male % all male
16 19
7 8
24 29
12
6
3
15
7
4
7
1
0
1
5
82
9
1
1
6
Female
33
6
25
(75)
66
7
2
(32)
29
2
1
5
2
178
TABLE IV.-Histogenetic variety of melanoma lesions
Male % male Female
Lentigo maligna 10 12 24
Superficial spreading 39 47 88
Nodular 25 30 39
Acral lentiginous 5 6 8
Subungual 1 1 2
Unclassified 2 3 17
Total
male
39
27
5
9
2
82
Incidence/105
2-8
4-7
1-9
4-6
2-1
3 -5
Total
female
102
40
13
14
9
178
Incidence/105
6-9
6-5
5*0
6-7
9 3
6-6
% all female
19
3
14
37
4
1
16
1
3
1
% female
13
49
22
4
2
9
77
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TABLE V.-Tumour thicknes8 mea8ured by Breslow technique
Thickness (mm)
0-0 99
1-1 99
2-2 2 99
3-3 3.99
4+
Missing
Males
19
10
11
6
28
8
82
0 males
23
12
13
7
34
10
Females
49
34
21
19
36
20
178
% females
28
19
12
11
20
11
Registration Scheme (Kemp, personal
communication).
More detailed comparison of the num-
bers reveals that the discrepancy is due
to previous under-registration of cases in
the West of Scotland. As the population
of this region is 56% of the whole of
Scotland the effect on the national figures
is considerable.
The distribution by age and sex of the
patients is shown in Table II, which also
shows the ratio of females at risk to males
at risk affected in each decade. Table III
details the site of primary tumours for
males and females. Table IV records the
histogenetic type of the primary tumour,
and Table V details the thickness of the
tumour, measured by the technique advo-
cated by Breslow (1977). This involves
the use of an ocular micrometer to
measure (in mm) the thickness of the
tumour from the overlying granular
layer in the epidermis to the deepest
invasive tumour cell.
DISCUSSION
The details recorded in the first year's
work of the Scottish Melanoma Group
indicate that at the present time 260
patientswithprimary, cutaneousmelanoma
present annually. The incidence of 5-1/105
p.a. is difficult to compare with figures for
other cancer registries in the U.K., as
those published for Oxford and East
Anglia relate to the periods 1962-1970
and 1961-1971 (Bakos & MacMillan,
1973; Sverdlow, 1979). With a tumour
the incidence of which is changing rapidly
comparisons should, if possible, be made
for the same calendar year.
Comparisons of our figures with those
from New South Wales (22/105 in 1976),
Queensland (32/105 in 1977) and Norway
(10*9/105 in 1977) suggest however that
as yet cutaneous malignant melanoma
does not affect as large a proportion of the
Scottish population as in Australia and
Scandinavia (McCarthy et al., 1980; Little
et al., 1980; Magnus, 1981). In each of
these 3 studies a rapidly increasing
incidence of malignant melanoma in the
area under study is reported, with a
doubling in incidence rate over each
7-9 years. If the genotype of the Austra-
lian and Scottish populations are indeed
similar, itwouldappearthatenvironmental
factors in Queensland increase the current
incidence of malignant melanoma 5-6
fold.
It will be seen from Table II that the
ratio of affected females to males shows
an excess of females in all decades. These
ratios are in broad agreement with the
figures recently published for England
and Wales for the earlier period 1968-71,
and add circumstantial evidence to the
suggestion that in relatively low-inci-
dence areas a hormonally dependent or
related aetiological factor results in a
higher incidence in premenopausal females
than in males of the same age range
(Lee & Storer, 1980).
The ratio of 2 females to one male is
similar to that reported in other countries
with a relatively low incidence of melano-
ma, whereas in countries such as Australia
with a high incidence the two sexes tend
to be affected equally (Lee & Storer,
1980). Comparison with figures collected
in Norway for 1977 shows an incidence
in males and females which is equal at
10.9/105 in 1977 and an increase of
-7% p.a. is reported (Magnus, 1981).
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This contrasts strongly with the striking
female male ratio in Scotland of 2.17%.
It will be of interest to see whether or
not this sex difference becomes less
marked if the Scottish figures rise to
levels approaching those for Norway.
Table III illustrates the high preponder-
ance oflesions on the lower leg in females.
Once again this is a common finding in
other large published series.
The work of Clark, Breslow, Balch and
their associates in the past decade has
greatly extended the volume of useful
information, often of considerable prog-
nostic significance, which can be obtained
from light-microscopic examination of
appropriate blocks of paraffin-embedded
tissue (Clark et al., 1969; Breslow, 1977;
Breslow & Macht, 1978; Balch et al., 1978,
1979, 1980). Clark has suggested that
there are several different histogenetic
precursors or lateral growth phases of
the pre-invasive epidermal component of
cutaneous malignant melanoma. The 4
main histogenetic varieties of melanoma
currently recognised are lentigo maligna,
superficial spreading, nodular and acral
lentiginous. Of these, the commonest
in large reported series is the superficial
spreading variety, and it will be seen that
the Scottish figures (48%) also show
this trend (Table IV). It is ofinterest that
a higher proportion of lentigo maligna
melanomas were diagnosed in Queensland
in 1977 than in 1966 (Little et al., 1980).
The 1977 figures from this Australian
state are 15.6% in males and 14.1%
in females, whereas the SMG figure for
1979 is 130%. There is strong circumstantial
evidence that cumulative total lifetime
exposure to solar radiation plays a
significant role in the aetiology of lentigo
maligna melanoma (McGovern et al.,
1980) whereas the available evidence for
superficial spreading and nodular mela-
noma suggests that intermittent sun
exposure and burning may be a more
important aetiological feature (Lancet,
1981). Nodular malignant melanoma is a
lesion with no residual evidence of any
in situ or lateral growth phase in the
6
epidermis, and only a vertically invasive
component. Our current understanding of
the biological processes underlying malig-
nant transformation would suggest that
this lesion is not ab initio an aggressive
vertically invasive lesion, but rather that
the rapid rate of tumour expansion in
this situation has obliterated all evidence
of an in situ or pre-invasive phase.
This group, which generally forms the
majority of deeply invasive poor-prog-
nosis tumours, currently comprises 25%
of the Scottish series.
It will be seen from Table V that in
1979 63 patients (24%) had tumours
> 4 mm thick. It is now well established
that there is an inverse linear relationship
between tumour thickness and survival
and figures from other studies suggest
that the 5-year survival rate for patients
with lesions of this thickness is only
38%, even after adequate and extensive
surgical excision (Pondes et al., 1981).
This therefore is a group in which studies
of appropriate adjuvant therapy are
urgently needed.
This would appear to be the first
occasion on which a population-based
group has had accurate histogenetic
typing and measurement of tumour thick-
ness carried out at the time of diagnosis.
This is significant, as in retrospective
studies lack of provision of suitable
blocks may reduce the accuracy of these
assessments.
If present trends continue the SMG
will have accumulated extensive clinical
and pathological information on 2500
patients with malignant melanoma by
1990. Much basic information on the
incidence, morbidity and modes of treat-
ment of this tumour will have been
collected, and careful analysis of this
data should allow valid conclusions to
be reached about changes in its incidence,
management, andbehaviourinthe Scottsh
population.
All population figures in this paper are taken from
the Annual Return of the Registrar General for
Scotland, December 1979.
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